drugset
drugset / Trial / NCT00998920

Multi-Dose Safety and Pharmacokinetic Study of S-Equol in Healthy Volunteers

NCT00998920 ↗

Phase 1 Completed 41 enrolled Ausio Pharmaceuticals, LLC
RandomizedSingle-groupDouble-blind

Summary

The purpose of this study is to evaluate the safety and tolerability of escalating multiple doses of S-equol administered twice daily (BID) for 14 days to healthy male and female subjects and to describe the pharmacokinetic profile of S-equol.

Timeline

Start
2008-12
Primary completion
2009-04
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Subject AUS-131 Small molecule 10 mg Oral
Subject AUS-131 Small molecule 20 mg Oral
Subject AUS-131 Small molecule 40 mg Oral
Subject AUS-131 Small molecule 80 mg Oral
Subject AUS-131 Small molecule 160 mg Oral

Indications

No indication recorded.